The Assay After Approval: A UK Biomarker Lab’s NICE-Ready Paper Trail

A biomarker assay can look finished in the lab long before it is finished in the system. You have the validation pack, the SOPs and a folder of precision data. Then someone asks a different question: what changes for the patient, and who pays for that change? In the UK, that question arrives through NICE diagnostics guidance, early value assessment, NHS commissioning and local formulary decisions. The bench work matters, but it is not the whole reimbursement story.

Validation is not the same as clinical utility

Analytical validation tells you the assay measures what it claims, reliably. Clinical utility tells everyone else whether using it improves care. Those are separate evidence piles, and the second one is often thinner than labs expect.

Start with a one-page intended-use statement: which patients, at what point in the pathway, and what clinical decision should the result change? Then map the current pathway. Is the comparator an existing lab test, imaging, a specialist referral or clinical judgement alone? If the assay slots into a pathway without displacing anything, commissioners will ask harder questions about budget impact.

Bench scientists can capture useful clinical utility evidence without running a trial. A local audit can record whether results changed referral behaviour, repeat testing, treatment selection or follow-up intervals. Even a small prospective audit, properly governed, is stronger than a claim that the test is “more sensitive” with no pathway consequence attached. Record negative findings too. A biomarker that rules out a costly investigation may be valuable, but only if the avoided pathway is documented.

NICE has more than one door

NICE diagnostics guidance is the best-known route, but it is not the only one. Early value assessment is designed for technologies with promising but incomplete evidence, and it often comes with an evidence-generation plan. Medtech innovation briefings describe products without making a commissioning recommendation. Many biomarker tests never go through NICE at all; they are commissioned locally or adopted through trust and integrated care board decisions.

The practical point is that the evidence expectations rhyme. A lab that has documented intended use, comparator, clinical utility and cost can reuse that material across routes. A lab that has only analytical data starts from scratch each time.

The paperwork to start before anyone asks

A useful 2026 rehearsal checklist for UK biomarker labs looks like this:

• Intended-use statement: one page, plain English, no assay brochure language.
• Pathway map: where the test sits, who orders it, what happens next and expected turnaround.
• Comparator: the current standard, including clinical judgement where relevant.
• Clinical utility log: local audit outcomes, decision impact and any safety signals.
• Cost inputs: consumables, staff time, quality control, retests, equipment depreciation and overhead — not just kit price per sample.
• Capacity model: runs per week, batching, staffing, cover, equipment redundancy and scale-up limits.
• Coding route: SNOMED CT and local pathology test codes agreed with IT and finance.
• Governance pack: UK GDPR basis, consent or anonymisation approach, and ISO 15189 accreditation evidence through UKAS where applicable.
• Budget impact: a simple local model for the trust or integrated care board, not only a cost-per-test figure.

The coding conversation nobody schedules

Coding is where good assays can become invisible. If the test has no agreed code, it may not be orderable, countable or reimbursable in the way the business case assumes. Talk to pathology IT, finance and commissioning early. Record the assay name, method, specimen type, turnaround and intended pathway. Check that you are not creating a duplicate of an existing code or hiding the test inside a generic category.

This is not glamorous, but it is operational evidence. A commissioner can support a test in principle and still fail to implement it because the order set, reporting template or coding route was never built.

Capacity is a health-economic variable

A test that takes three days because it is batched twice a week may deliver less clinical benefit than the evidence review assumes. Document your real capacity: staff training, quality control, external quality assessment, equipment downtime and weekend cover. Then show what would need to change to scale. Commissioners are not only buying an assay; they are buying a service that has to run on a Tuesday in February.

Run the rehearsal before the real panel

Hold a mock commissioning panel with a lab lead, finance colleague, clinician and patient representative. Present the one-page dossier and ask what is missing. Red-team the budget impact. Check whether the clinical utility evidence actually matches the intended-use claim. Keep version control, because pathways change and old assumptions linger in slide decks.

The goal is not to write a NICE submission alone from the bench. It is to make the evidence findable, honest and reusable when health economists and commissioners come calling. The NICE line is a gate, not a finish line. Labs that bank clinical utility, coding and capacity evidence early spend less time reconstructing their own story later.